Lite Strategy (LITS) Common Equity (2011 - 2026)
Lite Strategy (LITS) posted quarterly Common Equity of $56.8 million for Q1 2026, up 190.86% year-over-year from $19.5 million in Q1 2025, and down 30.56% quarter-over-quarter from $81.8 million in Q4 2025.
Lite Strategy (LITS) Common Equity (2011 - 2026) Analysis & Trends
Lite Strategy's Common Equity history runs 16 years deep, the most recent figure standing at $56.8 million for Q1 2026.
- In Q1 2026, Common Equity rose 190.86% year-over-year to $56.8 million; the TTM figure through Mar 2026 stood at $56.8 million (up 190.86% YoY), while the FY2025 annual figure was $16.9 million, down 48.73% from the prior year.
- Common Equity for Q1 2026 stood at $56.8 million, down from $81.8 million in the prior quarter.
- The five-year high for Common Equity was $112.3 million in Q3 2025, with the low at $16.9 million in Q2 2025.
- The 5-year median for Common Equity is $48.4 million (2022), against an average of $48.5 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity plunged 69.42% in 2024, then surged 351.28% in 2025.
- Lite Strategy's Common Equity stood at $48.4 million in 2022, then advanced by 22.98% to $59.5 million in 2023, then sank by 62.85% to $22.1 million in 2024, then surged by 270.4% to $81.8 million in 2025, then slumped by 30.56% to $56.8 million in 2026.
- Business Quant data shows LITS's Common Equity at $56.8 million in Q1 2026, $81.8 million in Q4 2025, and $112.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 9.79 Bn |
| 10 | Lite Strategy | 36.78 Mn | 29.24 Mn | - | 56.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.84 Mn |
| Dec 31, 2025 | 81.85 Mn |
| Sep 30, 2025 | 112.27 Mn |
| Jun 30, 2025 | 16.93 Mn |
| Mar 31, 2025 | 19.54 Mn |
| Dec 31, 2024 | 22.10 Mn |
| Sep 30, 2024 | 24.88 Mn |
| Jun 30, 2024 | 33.02 Mn |
| Mar 31, 2024 | 51.03 Mn |
| Dec 31, 2023 | 59.49 Mn |
| Sep 30, 2023 | 81.36 Mn |
| Jun 30, 2023 | 24.62 Mn |
| Mar 31, 2023 | 34.35 Mn |
| Dec 31, 2022 | 48.37 Mn |
| Sep 30, 2022 | 37.31 Mn |
| Jun 30, 2022 | 52.41 Mn |
| Mar 31, 2022 | 67.81 Mn |
| Dec 31, 2021 | 73.33 Mn |
| Sep 30, 2021 | 34.30 Mn |
| Jun 30, 2021 | 49.47 Mn |